LawFlash

Healthcare Policy Changes and Reform Expected Following the 2026 Midterm Elections

November 19, 2026
15 minute read

Key Takeaways

  • The 2026 US midterm election results are expected to drive significant changes in healthcare policy, with healthcare costs influencing legislative priorities.
  • Democratic control of both chambers of Congress is expected to increase scrutiny of existing healthcare policies and advance reform proposals, although significant legislative changes may face presidential and procedural obstacles.

The November 3, 2026 US midterm elections resulted in Democratic gains in and control of both the US House of Representatives and Senate, ending unified Republican control of Congress. Concerns about the cost of living, with healthcare expenses at the forefront, were a driving influence for many voters. Voter assessments of the Trump administration’s healthcare policies were largely negative, with majorities saying these policies worsened their healthcare costs and access to care. Although significant legislative changes would require presidential approval or sufficient congressional support to overcome a veto, Democratic control of Congress is expected to increase oversight of existing healthcare policies, advance legislative proposals, and create opportunities for targeted bipartisan reforms.

TARGET ISSUES

Medicaid Cuts and Work Requirements

Lawmakers may seek to repeal, delay, or modify provisions of the One Big Beautiful Bill Act (OBBBA) that are expected to cut $911 billion in federal Medicaid spending by 2034. Key targets may include the restrictions on provider taxes, which all states except Alaska use to finance their share of Medicaid spending and secure federal matching funds.

Lawmakers may also seek to revisit limitations on Medicaid managed care state-directed payments (SDPs), which generally reduced permissible payment ceilings from average commercial rates to Medicare-based rates. An estimated $60 billion in current federal Medicaid spending on hospital SDPs would exceed the new limits once fully implemented, with uncertainty as to how hospitals or states will find replacement funds.

Medicaid work requirements, which generally must be implemented by January 1, 2027, are also likely to face scrutiny due to the expected coverage losses exceeding 5 million individuals. The requirements apply in 44 states (including the District of Columbia) to nonexempt adults enrolled through the ACA Medicaid expansion or certain Section 1115 waiver programs, who must complete at least 80 hours per month of qualifying work or other community engagement activities.

Prior state implementation efforts raised concerns about digital literacy, eligible individuals losing coverage, and no corresponding employment gains. On November 13, 2026, the Centers for Medicare and Medicaid Services (CMS) announced an optional hold-harmless period through June 30, 2027. States electing the period must continue assessing whether individuals meet the requirement or qualify for an exclusion, but will not deny applications or disenroll otherwise eligible individuals solely for failure to meet the requirement during the period.

One to Watch: Rep. Hakeem Jeffries (D-NY), incoming House speaker, who indicated Medicaid is a top priority for the new legislative session.

Hospital and Physician Payment Cuts

The 2026 midterm elections may provide Congress an opportunity to revisit Medicare hospital and physician payment policies. In the final 2027 Hospital Outpatient Prospective Payment System (OPPS) rule, announced November 4, 2026, CMS reduced Medicare reimbursement for 340B drugs from Average Sales Price (ASP) plus 6% to ASP minus 28%, effective January 1, 2027.

CMS estimates first-year reductions of $4.35 billion in Medicare payments and $1.1 billion in beneficiary payments. As discussed in our July 21, 2026 LawFlash, the policy reintroduces 340B reimbursement cuts previously invalidated by the US Supreme Court in American Hospital Association v. Becerra, raising questions about whether CMS has cured the statutory flaws. To maintain budget neutrality, non-drug outpatient services will receive an estimated 7.5% increase in payments to offset the reduction in 340B drug payments.

Physicians will face baseline Medicare payment reductions in 2027. In the final 2027 Medicare Physician Fee Schedule (PFS) rule, announced November 4, 2026, CMS finalized conversion factor decreases of 1.83% for qualifying alternative payment model (APM) participants and 2.31% for nonqualifying participants, largely reflecting the expiration of the temporary 2.5% increase enacted under the OBBBA for 2026. Physician stakeholders have urged Congress to extend the increase to offset rising practice costs and 2026 reductions in indirect practice expense adjustments that reduced payments for facility-based services by approximately 7%.

CMS also finalized a 20% reduction in payments for certain office/outpatient evaluation and management (E/M) visits furnished on the same day as zero-day global procedures by the same physician or same-specialty group; thereby paying the highest-valued service at 100% and additional services at 80%. Although narrower than initially proposed, this policy has raised concerns about the financial sustainability of independent physician practices.

ACA Marketplace Subsidies and Tax Credits

Following the 2026 midterm elections, Congress may revisit Affordable Care Act (ACA) premium tax credit enhancements and Marketplace eligibility restrictions. Following the expiration of enhanced premium tax credits at the end of 2025, average Marketplace premium payments increased by 58% in 2026, contributing to declining enrollment. The expiration of the enhanced credits is projected to result in approximately 4.2 million additional uninsured individuals by 2034.

Beginning January 1, 2027, the OBBBA will restrict Marketplace subsidies (i.e., premium tax credits and cost-sharing reductions) for certain lawfully present immigrants, including refugees and asylees without permanent resident status and individuals holding certain work visas. The provision is expected to reduce federal spending by $91.4 billion and increase the uninsured population by approximately one million by 2035.

The OBBBA and its implementing regulations also imposed pre-enrollment eligibility verification, restricted certain special enrollment periods, and eliminated income-based caps on repayment of excess premium tax credits, potentially requiring low-income enrollees whose actual income exceeds their estimates to repay the full amount of excess subsidies received.

Additionally, individuals who lose Medicaid coverage as a result of the OBBBA's new work requirements will generally be ineligible for subsidized Marketplace coverage. Collectively, the OBBBA's healthcare coverage provisions, including changes to Medicaid and the ACA Marketplaces, are projected to increase the uninsured population by approximately 10 million by 2034. A larger uninsured population may drive greater emergency department utilization, hospital uncompensated care, and pressure on state and local healthcare funding.

Private Equity in Healthcare

Private equity in healthcare has been a focal point of federal government scrutiny for several years, but healthcare providers and investors should anticipate even greater congressional oversight of private equity’s role in healthcare delivery, as well as growing support for federal legislation focused on ownership restrictions and transparency. In the leadup to the midterm elections, Democratic lawmakers, including Senators Elizabeth Warren, Ron Wyden, and Edward Markey, raised concerns about the impact of private equity ownership on patient care, healthcare costs, staffing, and physician autonomy, advancing proposals such as the Stop Corporate Takeovers of Physicians Act of 2026, which would restrict corporate ownership and control of medical practices and limit the authority of management services organizations, and the Health Over Wealth Act, which would impose additional transparency and accountability requirements on private equity-owned healthcare entities.

Even with the gains Democrats have made in both chambers, such sweeping legislation may be delayed by more moderate Democrats or a presidential veto. But Democratic control of key congressional committees is likely to accelerate hearings, investigations, and document requests examining ownership structures, financial arrangements, consolidation, staffing decisions, and patient outcomes. Private equity-backed healthcare organizations should therefore be prepared for greater scrutiny of their governance and operational practices, including whether financial incentives or investor influence compromise clinical independence, quality of care, or patient access.

One to Watch: Sen. Elizabeth Warren (D-MA), who sponsored the Stop Corporate Takeovers of Physicians Act of 2026.

Antitrust Scrutiny of Healthcare

Healthcare providers, private equity sponsors, and other healthcare investors should anticipate heightened antitrust scrutiny under a Congress controlled by Democrats, particularly with respect to healthcare consolidation, serial acquisitions, labor markets, and the use of artificial intelligence and pricing algorithms. Although federal antitrust enforcement remains within the jurisdiction of the Federal Trade Commission (FTC) and the US Department of Justice (DOJ), Democratic control of key congressional committees is likely to increase oversight hearings, investigations, and legislative proposals focused on competition in healthcare markets.

Separately, changes in state attorney general leadership following the elections may influence state antitrust enforcement priorities, particularly in jurisdictions where healthcare competition has been an area of focus. State enforcers have increasingly challenged healthcare mergers, investigated alleged anticompetitive conduct by healthcare systems, and pursued claims involving labor market restrictions, reimbursement practices, and competition in local healthcare markets.

Healthcare organizations should also anticipate increased scrutiny of information-sharing practices, benchmarking activities, joint contracting arrangements, and the use of algorithmic tools that influence pricing, reimbursement, or other competitive decisions. Recent enforcement activity has demonstrated regulators' willingness to examine whether the exchange of competitively sensitive information or the use of common technology platforms could facilitate coordination among competitors. As healthcare organizations increasingly rely on artificial intelligence and data analytics to optimize operations, regulators may seek to evaluate whether these tools affect competition, labor markets, or consumer prices.

State Attorney General Changes

Healthcare organizations and other regulated businesses should anticipate potential shifts in state attorney general (AG) enforcement priorities following the 2026 midterm elections, which saw Democrats flip five Republican-held AG offices in Georgia, Iowa, Kansas, Ohio, and Texas, with no corresponding Republican gains. These changes could reshape the composition and priorities of multistate investigations and litigation coalitions, particularly in areas involving consumer protection, healthcare, competition, and corporate conduct. For healthcare organizations, potential areas of focus include healthcare affordability, pharmaceutical practices, competition among healthcare providers, and consumer-facing healthcare services. However, enforcement priorities will vary by state, and bipartisan cooperation on issues of shared concern is likely to continue.

In Texas, Democrat Nathan Johnson’s election marks the first time a Democrat has won the AG’s office since 1994 and signals a potential shift in the healthcare litigation and enforcement priorities of outgoing Attorney General Ken Paxton. Johnson has announced plans to review pending lawsuits and investigations initiated under Paxton and potentially discontinue matters he determines were pursued primarily for political purposes. He has expressed skepticism about continuing litigation against drug manufacturers related to autism causes. He has also indicated that he intends to discontinue certain litigation against out-of-state providers of abortion medication, potentially changing the state's approach to reproductive healthcare enforcement without altering the underlying statutory restrictions. While emphasizing that he would evaluate the merits of individual cases before making final decisions, Johnson’s review of pending matters could therefore affect the direction of healthcare-related litigation involving pharmaceutical manufacturers and reproductive healthcare providers in Texas.

Johnson has also identified rebuilding the AG’s office and strengthening its core functions as priorities, with particular emphasis on consumer protection, antitrust enforcement, and market competition. He has also expressed interest in addressing emerging technologies and business practices, including the use of artificial intelligence and algorithmic pricing. In the healthcare sector, these priorities could translate into increased scrutiny of healthcare consolidation, pricing and reimbursement practices, consumer protection issues, and the use of AI or algorithmic tools in healthcare-related commercial activities.

Although the scope of these changes will depend on the incoming AG’s review of pending matters and allocation of enforcement resources, the shift in leadership could result in the discontinuation of certain Paxton-era litigation alongside increased scrutiny of other commercial practices. . Healthcare organizations should monitor the disposition of pending investigations and litigation, emerging enforcement priorities, and opportunities for continued bipartisan or expanded multistate investigations involving healthcare affordability, consumer protection, and competition.

Gender Affirming Care

Following the midterms, healthcare organizations may see increased congressional oversight of federal investigations of gender-affirming care practices and legislative efforts to reverse related funding restrictions. Building on Senators Edward Markey and Ron Wyden’s opposition to proposed CMS rule CMS-3481-P, which would prohibit hospitals participating in Medicare and Medicaid from providing gender-affirming care to transgender minors if finalized, Democrats could pursue reversals of federal restrictions through legislation and/or appropriations provisions Such efforts may address CMS's recently finalized rule restricting federal Medicaid and CHIP funding for certain gender-affirming care provided to minors, as well as restrictions involving federal employee health plan coverage and ACA coverage requirements for essential health benefits.

However, Senate procedural hurdles and a potential presidential veto make immediate legislative and/or appropriations reversals uncertain. Congressional oversight of DOJ’s investigations could build on House Judiciary Democrats’ inquiries into alleged prosecutorial misconduct in the Rhode Island Hospital subpoena litigation and Senator Sheldon Whitehouse’s request for an inspector-general investigation. Even if Congress pursues changes to federal funding restrictions, DOJ investigations may continue independently, creating ongoing legal, financial, and operational challenges for healthcare organizations providing gender-affirming care.

State election results may also temper Democrats’ willingness to prioritize these issues. Washington voters approved Initiative 638, requiring students seeking to compete in girls’ K–12 sports to submit a healthcare-provider statement verifying biological sex, and Colorado voters approved Proposition 135, restricting certain gender-affirming surgeries for minors and payment for those procedures. Similar to the complexities for legislative challenges on the federal side, these state level measures will also face legal headwinds; there’s already a lawsuit in Washington State seeking injunctive relief to prevent the initiative from taking effect in December 2026. In Texas, the incoming Democratic attorney general may reassess investigation and enforcement priorities, but Republican control of the state Senate presents a significant obstacle to any legislative repeal efforts of current laws such as SB 14’s prohibition on gender-affirming care for minors, enacted in 2023.

Artificial Intelligence at the Federal and State Levels

Healthcare providers, insurers, and technology companies should anticipate continued state-level legislative activity and heightened scrutiny of AI in healthcare, particularly as Democratic gains in state legislatures and governorships create additional opportunities to advance legislation addressing patient safety, transparency, algorithmic discrimination, and human oversight of clinical decision-making.

Democratic lawmakers have already advanced measures regulating AI in healthcare, including California’s SB 1120, which restricts the use of AI in utilization review and prohibits AI systems from independently denying or modifying medically necessary care, and AB 3030, which requires certain healthcare providers to disclose the use of generative AI in patient communications.

More recently, Colorado enacted HB 26-1139, establishing additional requirements for AI-assisted coverage determinations and human review, while Illinois enacted the Wellness and Oversight for Psychological Resources Act, restricting the use of AI to provide therapy and psychotherapy services. This array of state laws will complicate and potentially limit national platforms leveraging AI tools.

Meanwhile, on Capitol Hill, Democratic control of Congress could generate additional interest in federal legislation governing AI in healthcare, including proposals such as the bipartisan Doctors Not AI Act of 2026, which would regulate the use of AI in health insurance coverage determinations. Although comprehensive federal AI legislation, particularly in light of the Trump Administration’s Executive Order on AI, remains uncertain, state legislatures are likely to remain central to AI oversight. Healthcare organizations should therefore be prepared for evolving and potentially divergent state requirements governing AI transparency, clinical independence, human oversight, and patient protections.

One to Watch: Rep. Greg Landsman (D-OH), who sponsored the Doctors Not AI Act of 2026.

PBM Reform and Pharmacy Economics

Pharmacy benefit manager (PBM) reform has remained a significant bipartisan priority issue and will likely continue to be a focal point in the 120th Congress. Democratic control of both chambers will likely lead to aggressive scrutiny of PBM business practices, vertical integration, and pharmacy reimbursement from both legislative and congressional oversight perspectives.

Congress already enacted substantial PBM reforms in the Consolidated Appropriations Act 2026 (CAA), including requirements to delink PBM compensation from drug prices and rebates in Medicare Part D, increase transparency into PBM compensation and contracting, and strengthen oversight of PBM arrangements with employer-sponsored health plans. Democratic leadership is expected to focus on implementation and enforcement of these CAA requirements while pursuing additional reforms left unresolved by the legislation, particularly Medicaid PBM payment transparency, pharmacy reimbursement practices, and protections for independent and community pharmacies.

Notably, Senator Ron Wyden, who is expected to chair the Senate Finance Committee, previously joined Senator Mike Crapo in sponsoring bipartisan legislation addressing PBM compensation, Medicaid payment practices, and pharmacy access, while Representative Frank Pallone, who is expected to chair the House Energy and Commerce Committee, has a history of supporting PBM oversight. More structural PBM reforms may also receive attention as Senators Elizabeth Warren and Josh Hawley, together with Representatives Jake Auchincloss and Diana Harshbarger, have advanced bipartisan legislation that would prohibit common ownership of PBMs and pharmacies, which would significantly alter the pharmacy distribution landscape.

Anticipate that Democrat-led committees will likely utilize hearings, investigations, and information requests to examine rebate arrangements, affiliated-pharmacy steering, and the impact of consolidation on drug costs and pharmacy access. The 340B Drug Pricing Program will be another area to watch, particularly whether Democratic lawmakers pursue legislation protecting covered entities' use of contract pharmacies amid ongoing manufacturer restrictions, potentially affecting pharmacy access and 340B program revenue. Although major legislative changes may be constrained in the near term, the bipartisan foundation for PBM reform makes targeted legislation plausible, while enhanced congressional oversight could independently increase pressure on PBMs, insurers, manufacturers, and pharmacy operators to reassess contracting arrangements, pricing practices, and vertically integrated business models.

One to Watch: Senate Finance Committee, likely chaired by Ron Wyden (D-OR), which wields significant oversight authority and has generated several bipartisan bills impacting PBMs.

HOW WE CAN HELP

The 2026 midterm election results are expected to reshape the healthcare policy landscape, with affordability and costs driving legislative priorities, regulatory initiatives, and party strategies. Democratic control of Congress is expected to increase legislative activity and congressional oversight of healthcare policy, although the Trump administration will retain substantial authority over federal regulation and enforcement, potentially limiting the scope of near-term policy changes. Our lawyers stand ready to anticipate policy developments and identify opportunities to shape emerging policies through strategic advocacy and engagement with policymakers.